Rucaparib Vs Physician's Choice of Therapy for Prostate Cancer

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib verses treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

August 09, 2017

  • Clinical Trial Information

    Trial Contact: Ferry, Robert, P.; Walton, Sherri

    Trial Phone: 321-841-1077 ; 321.841.1907

  • Age Group: Adult

    Phase: Drug: Phase III

    Principal Investigator: Julio J. Hajdenberg, MD

    Sub Investigators: Daniel Ari Landau, MD;

    IRB No: 17.007.01

    Secondary Protocol No: TRITON3: CO-338-063

    Applicable Disease Sites: Metastatic Castration Resistant Prostate Cancer